City to offer free measles vaccines at Juneteenth event
The event will be from 5:30 p.m. to 10 p.m. Saturday, June 14 at Nations Tobin Park, 8831 Railroad Dr.
City officials also remind residents to regularly check the Measles Information Dashboard for updates on confirmed cases, demographic data, and vaccination status.
The dashboard is updated daily around 9 a.m. and is available at EPHealth.com under the Measles information page.
The City also said that anyone who was at El Paso International Airport from 11:15 to 11:45 a.m. May 31 and June 1-2 should monitor their symptoms and check their immunization status. People who were at the airport at that time were potentially exposed to the measles, the City said.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
4 days ago
- Medscape
Other GU Cancers Share Germline Mutation Rates Seen in Ovarian Cancer
This transcript has been edited for clarity. Hello. I'm Dr Maurie Markman, from City of Hope. I'd like to discuss a very interesting and controversial topic. The paper I'm discussing is 'Germline Pathogenic Variants Identified in Patients With Genitourinary Malignancies Undergoing Universal Testing: A Multisite Single-Institution Prospective Study,' published in the Journal of Urology . It has been well recognized for over a decade that patients with ovarian cancer need to have germline testing, independent of whether they have a family history of that particular cancer because we identified particular mutations — BRCA mutations, BRCA1 and BRCA2 — that may not be evident in the family by history but are very relevantpotentially for cascade testing of their family members later. Also, of course, in that setting, there are therapeutic implications for the use of PARP inhibitors. Increasingly, the discussion is about more universal testing for patients with breast cancer because of the incidences of BRCA and other mutations that are both relevant for treatment and for the question of genetic counseling for other members of the family. What about other tumor types? What about genitourinary (GU) cancers, as identified here? Should one take patients with all different kinds of GU tumors — prostate cancer, bladder cancer, kidney cancers, typically — and say there's a role for universal germline testing when a patient has been identified as having one of these cancers? To address this question, the group at the Mayo Clinic undertook comprehensive germline testing, examining for pathogenic germline variants at several sites from April 2018 to March 2020. This was a greater than 80-gene panel that was offered to patients. Today, that testing may be really quite different, but at that point it was greater than 80 genes that were tested for potential abnormality. A total of 601 patients enrolled with GU cancers. Again, this was across the sites and with GU cancers, regardless of a family history. There were 358 patients with prostate cancer, 106 with bladder cancer, and 137 with kidney cancer. Surprisingly, a majority of these patients, 86%, were male. Here is the important bottom line. Pathogenic germline variants, most with risk of high penetrance, were identified in 82 individuals, or 14% of the population. First, they were seen in almost the same percentage in kidney, bladder, and prostate cancer, and that 14% is not that far off. In fact, it's quite similar to the statement about ovarian cancer in terms of the overall population — 14% of the patients with GU cancer. Importantly, at this time, based on these data, fully 67% (or 2 of 3) patients had abnormalities that were potentially actionable. "Actionable" could mean a variety of things. It could mean there may be a therapy involved. It could mean that we need to talk to members of the family. They were not like, 'Oh, that's interesting, but there's nothing we can do about it.' For 2 out of 3, they could actually do something actionable. Importantly, of those 82 patients, 35% had at least one relative undergo cascade testing to examine for that variant. The bottom line here is that more than 1 of 8 patients in this unselected group of patients with GU cancers had a variant finding that was potentially pathogenic at the germline level. This would argue for — although there is going to be controversy and we need more data — universal testing, certainly of GU tumors, and one might ask for other tumor types. We need more data to confirm that. This would obviously be an extensive, new universal recommendation with costs associated with it, but this paper certainly raises that question that needs to be further examined. Thank you for your attention.
Associated Press
5 days ago
- Associated Press
LabConnect Partners with Kits4Life to Reduce Kit Waste and Advance Sustainable Clinical Trials
JOHNSON CITY, Tenn., Aug. 7, 2025 /PRNewswire/ -- As part of our ongoing commitment to environmental stewardship and industry leadership in sustainable clinical research, LabConnect is proud to announce our partnership with Kits4Life, an initiative of the MedSurplus Alliance. This collaboration reflects our broader ESG strategy and strengthens LabConnect's role as the world's most agile and responsible central laboratory services provider. Through this partnership, LabConnect will work with sponsors and clinical sites to identify and manage eligible kits for donation, reducing landfill waste while contributing to global health equity. Clinical trials are essential to developing life-changing therapies, but they can also generate significant material waste—particularly unused and expired specimen collection kits. These kits often contain high-quality medical materials that, when responsibly redirected, can have a second life in communities with critical healthcare needs. 'We are excited to partner with Kits4Life as a framework for recovering surplus clinical trial kits and ensuring they are ethically and safely donated to organizations,' states Julia Tarasenko, Chief Commercial & Strategy Officer at LabConnect. LabConnect's ESG strategy focuses on transforming clinical trials into a more sustainable and inclusive global enterprise. From carbon footprint reduction to ethical sourcing and community engagement, we are integrating environmental and social responsibility across the full lifecycle of clinical research. Our work with Kits4Life is one more way we are turning strategy into action—by diverting valuable materials from waste streams and redirecting them to improve lives. 'We believe that sustainability and scientific innovation are not mutually exclusive—they are mutually reinforcing. As the clinical research industry evolves, partnerships like this help chart a path forward where environmental responsibility and breakthrough therapies go hand in hand,' adds Tarasenko. About LabConnect LabConnect is the leading provider of Central Laboratory Services, FSP and Scientific Consulting, and Data Integration and Transformation Services for analytically and logistically complex studies such as immuno-oncology, cell and gene therapies, and rare & orphan diseases. LabConnect's unique combination of state-of-the-art technology, world-class laboratories, easy access to major and emerging markets, and extensive specialized testing expertise means that drug development companies can rely on one provider for all their central laboratory service needs. Learn more at and follow on LinkedIn. View original content to download multimedia: SOURCE LabConnect
Yahoo
6 days ago
- Yahoo
ZIEN Medical Technologies Achieves CE Mark
SALT LAKE CITY, Aug. 6, 2025 /PRNewswire/ -- ZIEN Medical Technologies ("ZIEN"), a portfolio company of Banner Capital, is pleased to announce achievement of its first CE Mark under the EU MDR (EU 2017/745) on behalf of its customer SAM Medical Products ( Founded in 2009 and based in Salt Lake City, ZIEN is a vertically integrated medical device contract design & manufacturing organization ("CDMO") providing product design & development, manufacturing, cost-down, packaging, sterilization, and quality & regulatory services to medical device companies. As part of ZIEN's capabilities, the ability to act as the "Legal Manufacturer (LM)" or "Manufacturer of Record (MoR)" allows ZIEN to serve as an accelerator to speed innovative technologies to the global market. With ZIEN's EU MDR and MDSAP certifications and ability to serve as LM/MoR technologies that would otherwise take a Medical Device company over 2+ years to reach certification can be brought to market in likely under a year. Combined with ZIEN's other innovative offerings such as packaging and sterilization services the overall combined cost and time savings to reach the market can be significant. SAM Medical Products is an innovator in devices targeted to serve patients undergoing emergency medical procedures. Having provided devices for fracture management, hemorrhage control, and respiratory management SAM Medical entered the Intraosseous Access Market to improve its ability to serve patients in these emergency situations. Having served patients in the USA, Canada, and other global regions SAM desired to reach patients in Europe. Through the existing relationship with ZIEN as a contract manufacturer of the IO products SAM Medical found in ZIEN an opportunity to help expand their capacity and market reach by using ZIEN to provide regulatory support as MoR for the IO product. This allows SAM Medical to focus on expanding other product introductions, and place attention on the market distribution of the IO products while ZIEN manages the ongoing regulatory and engineering support and maintenance of the IO. Kyle Sims, Director of Product Development for SAM Medical stated, "ZIEN's role as Manufacturer of Record allows us to expand our engineering and product support capacity by transitioning the regulatory and technical oversight of this strong IO product line to their team. This partnership enables our internal teams to focus on building out the broader SAM Medical portfolio and gives us a scalable path to deliver more patient solutions as we grow our market presence." Tim Nieman, CEO of ZIEN, remarked "ZIEN has for over 16 years been serving our customers as an integrator of services allowing speed to market for medical devices. The EU MDR has resulted in increased barriers to the introduction of innovative technologies, stifling technology and causing supply bottlenecks. We have seen products that can help patients either be retracted from the EU market or fail to reach the EU due to the expense and complexities of achieving CE mark. ZIEN is pleased to once again be able to help our customers break through these barriers to provide care solutions that might otherwise not reach patients. With the EU MDR and MDSAP certificates and the experienced team here at ZIEN, we are poised to be able to develop, manufacture, and distribute, products that can bring care to patients worldwide while simultaneously reducing the time and expense of doing so. We believe that this service offering reduces the time to global market for a product by up to 2 years and by more than $100,000. Our partnership with SAM Medical allows us to bring the benefits of the SAM Medical IO products to patients in the EU that have to date been unable to have access to this product." Media Contact: Tim Nieman, View original content to download multimedia: SOURCE ZIEN Medical Technologies LLC Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
